BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22558221)

  • 1. Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand.
    Chootong P; Panichakul T; Permmongkol C; Barnes SJ; Udomsangpetch R; Adams JH
    PLoS One; 2012; 7(4):e35769. PubMed ID: 22558221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of Duffy binding protein region II polymorphisms and its antigenicity in Plasmodium vivax isolates from Thailand.
    Chootong P; McHenry AM; Ntumngia FB; Sattabongkot J; Adams JH
    Parasitol Int; 2014 Dec; 63(6):858-64. PubMed ID: 25108177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.
    Ntumngia FB; Schloegel J; McHenry AM; Barnes SJ; George MT; Kennedy S; Adams JH
    Vaccine; 2013 Sep; 31(40):4382-8. PubMed ID: 23916294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strain-Transcending Inhibitory Antibodies against Homologous and Heterologous Strains of Duffy Binding Protein region II.
    Wongkidakarn S; McHenry AM; Sattabongkot J; Adams JH; Chootong P
    PLoS One; 2016; 11(5):e0154577. PubMed ID: 27145131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.
    Ntumngia FB; Adams JH
    Clin Vaccine Immunol; 2012 Jan; 19(1):30-6. PubMed ID: 22116684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain.
    George MT; Schloegel JL; Ntumngia FB; Barnes SJ; King CL; Casey JL; Foley M; Adams JH
    mSphere; 2019 May; 4(3):. PubMed ID: 31092602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplexed Microsphere-Based Flow Cytometric Assay to Assess Strain Transcending Antibodies to
    Alves JRS; de Araújo FF; Pires CV; Teixeira-Carvalho A; Lima BAS; Torres LM; Ntumngia FB; Adams JH; Kano FS; Carvalho LH
    Front Immunol; 2021; 12():704653. PubMed ID: 34675915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic Variants.
    Kano FS; Souza-Silva FA; Torres LM; Lima BA; Sousa TN; Alves JR; Rocha RS; Fontes CJ; Sanchez BA; Adams JH; Brito CF; Pires DE; Ascher DB; Sell AM; Carvalho LH
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005177. PubMed ID: 27959918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of IgM and IgG responses to the next generation of engineered Duffy binding protein II immunogen: Strain-specific and strain-transcending immune responses over a nine-year period.
    Medeiros CMP; Moreira EUM; Pires CV; Torres LM; Guimarães LFF; Alves JRS; Lima BAS; Fontes CJF; Costa HL; Brito CFA; Sousa TN; Ntumngia FB; Adams JH; Kano FS; Carvalho LH
    PLoS One; 2020; 15(5):e0232786. PubMed ID: 32379804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP.
    Urusova D; Carias L; Huang Y; Nicolete VC; Popovici J; Roesch C; Salinas ND; Dechavanne S; Witkowski B; Ferreira MU; Adams JH; Gross ML; King CL; Tolia NH
    Nat Microbiol; 2019 Sep; 4(9):1486-1496. PubMed ID: 31133752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.
    Ntumngia FB; King CL; Adams JH
    Int J Parasitol; 2012 Nov; 42(12):1055-62. PubMed ID: 23068913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies.
    Chootong P; Ntumngia FB; VanBuskirk KM; Xainli J; Cole-Tobian JL; Campbell CO; Fraser TS; King CL; Adams JH
    Infect Immun; 2010 Mar; 78(3):1089-95. PubMed ID: 20008533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein.
    Grimberg BT; Udomsangpetch R; Xainli J; McHenry A; Panichakul T; Sattabongkot J; Cui L; Bockarie M; Chitnis C; Adams J; Zimmerman PA; King CL
    PLoS Med; 2007 Dec; 4(12):e337. PubMed ID: 18092885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans.
    Xainli J; Baisor M; Kastens W; Bockarie M; Adams JH; King CL
    J Immunol; 2002 Sep; 169(6):3200-7. PubMed ID: 12218138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and Characterization of Functional Human Monoclonal Antibodies to
    Carias LL; Dechavanne S; Nicolete VC; Sreng S; Suon S; Amaratunga C; Fairhurst RM; Dechavanne C; Barnes S; Witkowski B; Popovici J; Roesch C; Chen E; Ferreira MU; Tolia NH; Adams JH; King CL
    J Immunol; 2019 May; 202(9):2648-2660. PubMed ID: 30944159
    [No Abstract]   [Full Text] [Related]  

  • 16. Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein.
    Chen E; Salinas ND; Huang Y; Ntumngia F; Plasencia MD; Gross ML; Adams JH; Tolia NH
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6277-82. PubMed ID: 27194724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a vaccine against Plasmodium vivax malaria.
    Beeson JG; Crabb BS
    PLoS Med; 2007 Dec; 4(12):e350. PubMed ID: 18092888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-allele specific antibody responses to genetically distinct variant forms of Plasmodium vivax Duffy binding protein (PvDBP-II) in Iranians exposed to seasonal malaria transmission.
    Valizadeh V; Zakeri S; Mehrizi AA; Djadid ND
    Acta Trop; 2014 Aug; 136():89-100. PubMed ID: 24704284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.
    Ntumngia FB; Barnes SJ; McHenry AM; George MT; Schloegel J; Adams JH
    Clin Vaccine Immunol; 2014 Sep; 21(9):1215-23. PubMed ID: 24964808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein (PvDBP-II) equally block erythrocyte binding of homologous and heterologous expressed PvDBP-II on the surface of COS-7 cells.
    Valizadeh V; Zakeri S; Mehrizi AA; Mirkazemi S; Djadid ND
    Med Microbiol Immunol; 2016 Feb; 205(1):85-95. PubMed ID: 26243337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.